XML 145 R114.htm IDEA: XBRL DOCUMENT v3.26.1
Operating expenses - Narrative (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Research and development expenses    
Disclosure of attribution of expenses by nature to their function [line items]    
Increase (decrease) in Ulcerative Colitis expenses € 1,587 € 32,030
Increase (decrease) in Crohn's Disease research expenses 10,200 4,620
Increase (decrease) in transversal activities 12,987 € 8,233
Increase (decrease) in transversal activities, combination therapy 4,122  
Increase (decrease) in employer tax and social contributions 20,131  
General and administrative expense    
Disclosure of attribution of expenses by nature to their function [line items]    
Increase (decrease) in employer tax and social contributions € 27,299